Fig. 7

Fig. 7

a Quantification of lateral line neuromasts in the mock and AG1478-treated erbb3b^hg115 mutant embryos at 5 dpf. b Quantification of lateral line neuromasts in the mock and AG1478-treated nrg1^hg114 mutant embryos at 5 dpf. Approximately 40 embryos generated from a pair of heterozygous parents carrying either erbb3b^hg115 or nrg1^hg114 mutation were treated with 0 or 2 µM AG1478 from 1 to 5 dpf and then stained with Yopro-1 to count lateral line neuromasts. c Quantification of lateral line neuromasts in the gemin5^hg81/erbb3b^hg115 mutant embryos at 5 dpf. The data are generated from analyzing 177 embryos generated from pairwise incrosses of double heterozygous parents and five embryos are double mutants. d Quantification of lateral line neuromasts in the gemin5^hg81/nrg1^hg114 mutant embryos at 5 dpf. The data are generated from analyzing 156 embryos generated from pairwise incrosses of double heterozygous parents and 13 embryos are double mutants. eerbb2 mutation rate in erbb2 CRISPR guide RNA injected gemin5 mutant embryos at 5 dpf. Mutation rate was measured by CRISPR-STAT fluorescent PCR-based fragment analysis⁶¹. f Quantification of lateral line neuromasts in the mock and erbb2 CRISPR guide RNA injected gemin5 mutant embryos at 5 dpf. Error bars in the graphs indicate mean ± s.e.m. ns, P > 0.05; *P < 0.05; **P < 0.01; ****P < 0.0001. The analysis was done by injecting the embryos generated from a pair of gemin5^hg81 heterozygous parents with either Cas9 protein alone (mock injection) or Cas9 protein together with erbb2 guide RNAs (erbb2 gRNA injection), followed by analyzing hair cell development in ~40 injected embryos for each condition, and lastly determining gemin5^hg81 genotype and erbb2 mutation rate for each of the analyzed embryo. No erbb2 mutation was detected in the mock injection group.